Phase 1 Obesity Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 60 years of any race or gender
- People with obesity, defined as a body mass index (BMI) between 30 and 40 kg/m²
- People with insulin resistance, measured by a specific blood test score (called HOMA2-IR) greater than 2.2
- People with high blood pressure, either shown by two or more seated blood pressure readings above 130/85 mmHg, or by currently taking blood pressure-lowering medication
- People who are able and willing to give their informed consent to participate
Who may not be able to join:
- People who are pregnant or breastfeeding
- People who currently smoke or have a history of heavy smoking (more than 2 packs per day)
- People with a history of alcohol or drug abuse
- People with severe obesity (BMI above 40 kg/m²)
- People who have previously had an allergic reaction to the medications used in this study
- People with type 1 or type 2 diabetes, including those with a fasting blood sugar above 126 mg/dl or those taking diabetes medications
- People with heart conditions other than high blood pressure, such as a heart attack within the past 6 months, chest pain (angina), serious irregular heartbeat, heart failure, blood clots in the legs or lungs, certain heart rhythm or valve problems, or a thickened heart muscle
- People with a history of serious brain or blood vessel conditions, such as a brain bleed, stroke, or mini-stroke (TIA)
- People with a history or current diagnosis of immune system or blood disorders
- People with poor liver function, based on specific blood test results
- People with poor kidney function, based on a blood test showing creatinine levels above 1.5 mg/dl
- People with anaemia (low haemoglobin levels — below 13.5 g/dl in males or below 12.5 g/dl in females)
- People currently being treated with a class of antidepressants called SNRIs, or medications that affect a protein called the norepinephrine transporter (NET) (confirm with trial site)
- People currently taking medications known as phosphodiesterase 5 inhibitors (used for conditions such as erectile dysfunction or pulmonary hypertension)
- People currently taking blood-thinning (anticoagulant) medications
- People who have taken steroid medications (glucocorticoids) for more than 7 days in a row within a single month
- People who have taken part in another clinical drug trial within the month before this study
- People who are unable to give or withdraw their informed consent
- People who, in the opinion of the trial investigators, have other health or personal factors that would prevent them from completing the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Alfredo Gamboa, MD, Vanderbilt University Medical Center
Phone: 615-421-1994
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Whole-Body Insulin Sensitivity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.